Bio-Rad Laboratories, Inc. (BIO)
NYSE: BIO · Real-Time Price · USD
342.64
-5.22 (-1.50%)
Aug 6, 2026, 4:00 PM EDT - Market closed
Bio-Rad Laboratories Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 222.4 | 759.9 | -1,844 | -637.3 | - | - |
Depreciation & Amortization | 168.7 | 165.4 | 151.6 | 145.9 | - | - |
Stock-Based Compensation | 60.3 | 58 | 62.3 | 61.3 | - | - |
Other Adjustments | -173.7 | -508.8 | 2,122 | 956.2 | - | - |
Change in Receivables | 21.3 | 19.6 | 16.2 | 11.4 | - | - |
Changes in Inventories | 27.5 | 68.9 | 8.5 | -46.3 | - | - |
Changes in Accounts Payable | -8.5 | -0.1 | -40.9 | -51.8 | - | - |
Changes in Income Taxes Payable | 51.7 | 1.5 | 24.1 | -21.3 | - | - |
Changes in Other Operating Activities | -61.2 | -32.2 | -44.7 | -43.2 | - | - |
Operating Cash Flow | 492.6 | 532.2 | 455.2 | 374.9 | 194.4 | 669.46 |
Operating Cash Flow Growth | -7.79% | 16.92% | 21.42% | 92.85% | -70.96% | 14.44% |
Capital Expenditures | -139.5 | -157.6 | -165.6 | -156.7 | -112.8 | -133.75 |
Sale of Property, Plant & Equipment | - | 0.1 | 0.1 | 0.2 | 0.2 | 0.05 |
Purchases of Intangible Assets | - | - | - | - | -1.5 | -453.44 |
Purchases of Investments | -773 | -669.3 | -1,277 | -689 | -2,060 | -851.63 |
Proceeds from Sale of Investments | 676.1 | 855.6 | 1,305 | 863.2 | 1,066 | 766.9 |
Cash Acquisitions | -0.7 | -218.5 | -23.4 | - | -100.7 | -125.52 |
Proceeds from Business Divestments | - | - | - | 2.5 | 1.4 | - |
Investing Cash Flow | -237.1 | -189.7 | -160.2 | 20.2 | -1,208 | -797.38 |
Long-Term Debt Issued | - | - | - | - | 1,186 | - |
Long-Term Debt Repaid | -0.5 | -0.5 | -0.4 | -0.5 | -0.5 | -3.02 |
Net Long-Term Debt Issued (Repaid) | -0.5 | -0.5 | -0.4 | -0.5 | 1,186 | -3.02 |
Issuance of Common Stock | 14.9 | 15.8 | 19.2 | 18.5 | 17.6 | 20.63 |
Repurchase of Common Stock | -132.2 | -295.5 | -203.6 | -428.7 | -215.7 | -50 |
Net Common Stock Issued (Repurchased) | -117.3 | -279.7 | -184.4 | -410.2 | -198.1 | -29.37 |
Other Financing Activities | -3 | -3 | -34 | -14.9 | -14 | -23.04 |
Financing Cash Flow | -120.8 | -283.2 | -218.8 | -425.6 | 973.6 | -55.43 |
Foreign Exchange Rate Adjustments | 12.4 | -16.9 | 9.2 | 0.4 | 3 | -12.64 |
Net Cash Flow | 147.1 | 42.4 | 85.4 | -30.1 | -36.6 | -195.98 |
Free Cash Flow | 353.1 | 374.6 | 289.6 | 218.2 | 81.6 | 535.72 |
Free Cash Flow Growth | -4.83% | 29.35% | 32.72% | 167.40% | -84.77% | 12.45% |
FCF Margin | 13.64% | 14.50% | 11.28% | 8.17% | 2.91% | 18.33% |
Free Cash Flow Per Share | 13.11 | 13.73 | 10.26 | 7.47 | 2.74 | 17.73 |
Levered Free Cash Flow | 260.6 | 805.3 | -1,912 | -811.2 | -2,555 | 4,117 |
Unlevered Free Cash Flow | 72.4 | 81.93 | 144.78 | 79.84 | 259.34 | 256.88 |